ClinicalTrials.gg
Enrolling by invitationNCT06336525Updated Oct 27, 2025

Adult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities.

An observational study in Sleep Apnea, Insomnia and Sleep Deprivation, sponsored by Brigham and Women's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Brigham and Women's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
3,680
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital — 3 open to participants now, 3 under way, none of them phase 3. Sleep Apnea Syndromes · Brigham and Women's Hospital.

Started
2024
the only one that year
Observational
5 of 22
1 open now
Registered
19th of 22
by date

Among the 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital, this one is the only one that started in 2024, is one of 5 observational ones, and was the 19th registered.

Sleep Apnea Syndromes

1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.

Browse Sleep Apnea Syndromes studies →

Open to participants now

3 of the 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sleep Apnea Syndromes by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

Rural communities in the southern U.S. suffer a disproportionate burden of morbidity and mortality from cardiometabolic disease, with traditional risk factors explaining only a modest proportion of the excess burden of disease. There is considerable evidence that multiple dimensions of sleep health, including sleep duration, efficiency, timing, and regularity, as well as the disorders sleep apnea and insomnia, affect cardiometabolic disease risk. However, there is currently a lack of systematically developed sleep data in rural populations. The RURAL Sleep Study is an ancillary study to a recently initiated longitudinal epidemiology study in rural Appalachia and Mississippi Delta (the RURAL Study). The RURAL Sleep Study will add measures of sleep health to the complex individual, social and environmental factors and health outcome measures being evaluated by the RURAL Study, by incorporating minimally burdensome measures of multiple dimensions of sleep health. The results are expected to inform health care providers, public health officials, and the general public of the prevalence, risk factors, and consequences of impaired sleep health in these rural communities, providing a critical basis for prevention, recognition, and management of sleep disorders and improvement of sleep and cardiometabolic health.

Read the detailed description

Rural communities in the southern U.S. suffer a disproportionate burden of morbidity and mortality from cardiometabolic disease, with traditional risk factors explaining only a modest proportion of the excess burden of disease. Growing evidence implicates poor sleep health as an important risk factor for cardiometabolic disease. While this is most well established for sleep apnea and insomnia, there is considerable evidence that multiple dimensions of sleep health, including sleep duration, efficiency, timing, and regularity, also affect cardiometabolic disease risk. Moreover, rural Southern communities are likely to experience high rates of impaired sleep health, reflecting high levels of psychosocial and environmental stressors, such as financial stress, social isolation, environmental pollution, and poor built environment in addition to high rates of smoking and obesity. However, there is currently a lack of systematically developed sleep data in rural populations.

Recognizing the paucity of research on cardiometabolic risk in this high-risk rural population, the NHLBI recently initiated a new longitudinal epidemiology study in rural Appalachia and Mississippi Delta (the RURAL Study) to identify the complex individual, social and environmental factors contributing to this high burden of disease. The proposed RURAL Sleep Study will complement the RURAL Study by incorporating minimally burdensome measures of multiple dimensions of sleep health at the time of baseline cohort assessment in approximately 4000 adults age 25-64 years, utilizing mobile health technologies to

  1. measure sleep apnea over seven consecutive nights;
  2. measure sleep duration, timing, regularity and fragmentation over multiple weeks; and
  3. administer standardized questionnaires to assess insomnia, chronotype, sleep quality, sleep-related impairment, and fatigue.

These data will allow us to leverage the planned extensive assessments of cardiometabolic risk factors, subclinical disease, and psychosocial and environmental stressors (and resilience factors) to address the following specific aims:

Aim 1a. Quantify population distributions of sleep health measures in a rural cohort along dimensions of sleep apnea, insomnia, chronotype, and sleep duration, efficiency, timing, and regularity.

Aim 1b. Identify psychosocial, behavioral, and environmental correlates of sleep health in rural communities.

Aim 2. Assess the association of sleep health with cardiometabolic risk factors and subclinical cardiovascular disease independent of other established cardiovascular and metabolic risk factors.

The results are expected to inform health care providers, public health officials, and the general public of the prevalence, risk factors, and consequences of impaired sleep health in these rural communities, providing a critical basis for prevention, recognition, and management of sleep disorders and improvement of sleep and cardiometabolic health.

03

Conditions studied

  • Sleep Apnea
  • Insomnia
  • Sleep Deprivation
  • Sleep Disorders, Circadian Rhythm
  • Sleepiness, Excessive Daytime
  • Fatigue
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The cohort will consist of a general population sample of adults age 25-64 years residing in 10 counties in the rural Appalachia and Mississippi Delta regions (AMD): Alabama, Mississippi, Louisiana, and Kentucky, with counties sampled proportional to their populations. The projected RURAL Study sample size is 4600 individuals, with approximately equal numbers in each of the four age deciles. The sample is anticipated to include 51.7% women and 48.3% men. The projected racial/ethnic make-up of the sample is 63.8% non-Hispanic white, 32.7% non-Hispanic black, 1.7% Hispanic and 1.8% other.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants in the Risk Underlying Rural Areas Longitudinal (RURAL) Study will be eligible for enrollment in this ancillary study.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
3,680 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Oxygen desaturation index

    Frequency of 4% drops in nocturnal blood oxygen saturation

    Time frame: 7 nights

  2. Insomnia Severity Index

    min: 0, max: 28, higher score indicates more insomnia symptoms

    Time frame: Single measurement at baseline

  3. Sleep Duration

    Mean total sleep time from accelerometry

    Time frame: 3-6 months

  4. Sleep Duration Regularity

    Variability in total sleep time from accelerometry

    Time frame: 3-6 months

  5. Sleep Timing

    Sleep midpoint from accelerometry

    Time frame: 3-6 months

  6. Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-related Impairment Short Form 8a

    raw score min: 8, max: 40; higher score indicates greater impairment

    Time frame: Single measurement at baseline

Secondary outcomes

  1. Restless Legs Syndrome (RLS)

    Restless Legs Syndrome, yes/no

    Time frame: Single measurement at baseline

  2. Chronotype

    Body's natural tendency to go to sleep and wake up at certain times

    Time frame: Single measurement at baseline

  3. Sleep Timing Regularity

    Variability in sleep midpoint from accelerometry

    Time frame: 7 days

  4. Global Sleep Quality

    Pittsburgh Sleep Quality Index (PSQI), min: 0, Max: 21; higher score indicates poorer sleep quality Minimum Score = 0 (better); Maximum Score = 21 (worse) Interpretation: TOTAL \< 5 associated with good sleep quality TOTAL \> 5 associated with poor sleep quality

    Time frame: Single measurement at baseline

  5. Oxygen desaturation index, 3%

    Frequency of 3% drops in nocturnal blood oxygen saturation

    Time frame: 7 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified oximetry data and the results of sleep questionnaires will be shared via the National Sleep Research Resource (NSRR) (sleepdata.org). The RURAL sleep data will be available for any researcher who provides an acceptable Data Access and Use Agreement and has appropriate regulatory approvals. The NSRR has procedures to streamline Institutional Review Board (IRB) approval (via an in house IRB process). The NSRR is in the process of migrating to Bio Data Catalyst, enabling easy linkage and interoperability with other Bio Data Catalyst data (from RURAL) and other cohorts to individuals with approved Database of Genotypes and Phenotypes (dbGaP) authorization. Other RURAL Study data that are integral to this project but were collected separately by the parent RURAL Study (e.g., non-sleep cardiovascular risk and outcomes data) will be distributed via RURAL Study data sharing mechanisms, including via Bio Data Catalyst and dbGaP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Within one year of publication of primary study results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartActual
May 8, 2024
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06336525
Responsible party
Daniel J.Gottlieb, M.D.,M.P.H. (Medical Doctor, Brigham and Women's Hospital) — Principal investigator
First posted
Mar 28, 2024
Start date
May 8, 2024
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Oct 27, 2025

Study contacts

Daniel J Gottlieb, MD, MPH
principal investigator · Brigham and Women's Hospital
Tené Lewis, PhD
principal investigator · Emory University
Tianyi Huang, PhD
principal investigator · Harvard Chan School of Public Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion